COCRYSTALLIZATION ACYCLOVIR-SUCCINIC ACID USING SOLVENT EVAPORATION METHODS
Keywords:acyclovir, succinic acid, cocrystal, characterization, solvent evaporation method
Objective : The aim of this research is to prepare and characterize cocrystals of acyclovir through cocrystallization of acyclovir â€“ succinic acid (AS) to improve the physical properties of the drug. Â
Methods : AS cocrystals was prepared using solvent evaporation method. The cocrystals wereÂ characterized by Polarization Microscope, Scanning Electron Microscopy (SEM), Differential Scanning Calorimetry (DSC), Â Powder X-Ray Diffraction (PXRD), and Fourier Transform Infrared Spectroscopy (FTIR).
Results : Physical characterization using polarization microscope and SEM showed the AS cocrystals have unique crystal habit and morphology. Phase diagram at molar ratio of 50% : 50% (acyclovir : succinic acid) showed a decrease in the melting temperature i.e 176.23 oC Â in comparison with the melting point of the constituentÂ materials (acyclovir 253.53 oC and succinic acid 187.29 oC).Â The PXRD pattern of AS cocrystals (ethanol) exhibited new diffraction peaks at 2Î¸ = 5.91; 9.16; and 13.40. Besides, cocrystals of AS (glacial acetic acid) indicated new peaks atÂ 2Î¸ = 5.98; 9.19; and 13.43.Â Furthermore, there was a shift in the N-H, O-H and C=O.
Conclusion : Cocrystallization of acyclovir-succinic acid (AS) in ethanol and glacial acetic acid were succesfully formed using solvent evaporation methods.
Jones W, Motherwell WD, Trask AV. Pharmaceutical co-crystals: An emerging approach to physical property enhancement. MRS Bull 2006;31:875-9.
Shultheiss N, Newman A. Pharmaceutical and their physicochemical properties. Cryst Growth Des 2009;9:2950-67.
Sarma B, Chen J, Hsi H, Myerson AS. Solid forms of pharmaceuticals: Polymorphs, salts and co-crystals. Korean J Chem Eng 2011;28(2):315-22.
Sekhon BS. Pharmaceutical co-crystals - An update. Int Bull Drug Res 2012;1(2):24-39.
Mingyu L, Hong BC, Yao Y, Shen H, Ji G, Li G, et al. Development of a pharmaceutical co-crystal with solution crystallization technology: Preparation, characterization, and evaluation of myricetin-proline cocrystals. Eur J Pharm Biopharm 2016;107:151-9.
Sevukarajan M, Thanuja B, Riyaz S, Rahul N. Synthesis and characterization of a pharmaceutical co-crystal (Aceclofenac: Nicotinamide). J Pharm Sci Res 2011;3(6):1288-93.
Nanjwade VK, Manvi FV, Shamrez AM, Basavaraj KN, Meenaxi MM. New trends in the co-crystallization of active pharmaceutical ingredients. J Appl Pharm Sci 2011;1(8):1-5.
Santos OM, Reis ME, Jacon JT, Lino ME, Simoes JS, Doriguetto AC. Polimorphism: An evaluation of the potential risk to the quality of drug products from the farmacia popular rede propria. Braz J Pharm Sci 2014;50(1):1-24.
Almarsson O, Zaworotko MJ. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem Commun 2004;35(6):1889-96.
Najar AA, Azim Y. Pharmaceutical co-crystals: A new paradigm of crystal engineering. J Indian Inst Sci 2014;94(1):45-67.
Masuda T, Yoshihashi Y, Yonemochi E, Fujii K, Uekusa H. Co-crystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir. Int J Pharm 2012;422:160-9.
Bruni G, Maietta M, Maggi L, Mustarelli P, Ferrara C, Berbenni V, et al. Preparation and physicochemical characterization of acyclovir co-crystals with improved dissolution properties. J Pharm Sci 2013;102(11):4079-86.
Yan Y, Chen JM, Lu TB. Simultaneously enhancing the solubility and permeability of acyclovir by crystal engineering approach. Cryst Eng Commun 2013;15:6457-60.
Sarkar A, Rohani S. Co-crystal of acyclovir with promising physicochemical properties. J Pharm Sci 2015;104:98-105.
Munde AV, Kumar FN, Radheshyam BK. Co-crystallization: An alternative approach for solid modification. J Drug Ther 2013;3(4):166-72.
Partogi T, Soewandhi SN, Pamudji JS, Wikarsa S. Identification of physical interaction between anti malarial drugs combination artesunate-amodiaquine hydrochloride. Int J Pharm Pharm Sci 2013;5(3):206-10.
Setyawan D, Sari R, Yusuf H, Primaharinastiti R. Preparation and characterization of artesunate-nicotinamide co-crystal by solvent evaporation and slurry method. Asian J Pharm Clin Res 2014;7(1):62-5.
Alatas F, Soewandhi SN, Sasongko L, Ismunandar, Uekusa H. Co-crystal formation between didanosine and two aromatic acids. Int J Pharm Pharm Sci 2013;5(3):275-80.
Reutzel-Edens SM. Analytical techniques and strategies for salt, co-crystal characterization. In: Wouters J, Luc Q, editors. Pharmaceutical Salts and Co-crystals. RSC Drug Discovery Series No. 16. Cambridge: Royal Society of Chemistry Publishing; 2012. p. 220.
Allam AN, Naggar VF, El Gamal SS. Formulation and physicochemical characterization of chitosan/acyclovir co-crystals. Pharm Dev Technol 2013;18(4):856-65.
Brittain HG. Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker; 1999.
Barboza F, Vecchia DD, Tagliar MP, Silva MA, Stulzer HK. Differential scanning calorimetry as a screening technique in compatibility studies of acyclovir extended release formulations. Pharm Chem J 2009;43:363-8.
Ober CA, Gupta RB. Formation of itraconazole-succinic acid co-crystals by gas antisolvent cocrystallization. AAPS Pharm Sci Technol 2012;13(4):1396-405.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.